STUDY OF THE ROLES OF PTH RELATED PEPTIDE (PTHrp) IN REPRODUCTION AND GYNECOLOGIC TUMOR

PTH相关肽(PTHrp)在生殖和妇科肿瘤中的作用研究

基本信息

项目摘要

(1) PTHrP gene expression and presence of PTHrp molecule in normal female reproductive organs.(a) PTHrP gene expression was confirmed by means of RT-PCR in endometrium, decidua, villi, tube, ovary, and uterine muscle as well as fetal membrane and fetal liver, intestine and skin.(b) Immunohistochemical analysis showed that PTHrP was positively stained in endometrial cells in endometrium, endometrial cells, stromal cells in decidual tissue, chorionic cells, decidual stromal cells in fetal membrane, syntijtium in chorionic villi.(c) High concentration of PTHrP was present in milk of lactating puerperal women, in whom serum PTHrP concentration was high, suggesting the transfer of milk PTHrP to the blood stream of lactating puerperal women occured.(d) PTHrP concentration in amniotic fluid was the highest in second trimester during pregnancy. Amniotic fluid PTHrP concentration in hydroamnios and pregnancies with anomalous fetus was not different from normal controls expect for thanatophoric dwrafism in which PTHrP concentration was lower.(e) Follicular fluid contained high concentration of PTHrP.PTHrp levels seemed not tobe affected by estrogen or progesterone levels in follicular fluid.(2) PTHrP gene expression in tissues of ovarian benign and malignant tumors and clinical signific ance of PTHrP in patients with ovarian tumors.(a) PTHrP gene expression was seen in tissue of both benign and malignant tumors.(b) PTHrP concentration was determined by means of RIA in sera of patients with benign ovarian tumors (n=34), malignant ovarian tumors (n=27) and ascites and cystic fluid (from benign tumors, n=5, malignant tumors, n=10). High serum levels of PTHrP were seen in 8 % of cases with benign tumors and in 35 % of cases with malignant tumors. Concentration of PTHrP in asctic and cystic fluid was very high (more than 500 pmol/L) in 33 % of malignant cases. These results suggest that PTHrP determination is useful a tumor marker in some cases of ovarian tumors.
(1)正常女性生殖器官中PTHrP基因表达和PTHrp分子的存在。(a)RT-PCR检测子宫内膜、蜕膜、绒毛、输卵管、卵巢、子宫肌、胎膜、胎儿肝、肠、皮肤组织中PTHrP基因的表达。(b)免疫组化结果显示,PTHrP在子宫内膜细胞、子宫内膜细胞、蜕膜组织间质细胞、绒毛细胞、胎膜蜕膜间质细胞、绒毛合体中呈阳性表达。(c)哺乳期产妇乳汁中PTHrP含量高,血清中PTHrP含量也高,提示乳汁中PTHrP向哺乳期产妇血流中转移。(d)妊娠中期羊水PTHrP浓度最高。羊水过多和异常胎儿组羊水PTHrP浓度与正常对照组无显著性差异,但死亡性脱水组羊水PTHrP浓度较正常对照组低。(e)卵泡液中PTHrp含量较高,且不受雌、孕激素水平的影响。(2)卵巢良恶性肿瘤组织中PTHrP基因的表达及其临床意义(a)PTHrP基因在良、恶性肿瘤组织中均有表达。(b)本文用放射免疫分析法测定了34例卵巢良性肿瘤、27例卵巢恶性肿瘤、5例卵巢良性肿瘤、10例卵巢恶性肿瘤患者腹水及囊液中PTHrP的含量。良性肿瘤患者血清PTHrP水平明显升高,占8%;恶性肿瘤患者血清PTHrP水平明显升高,占35%。33%的恶性肿瘤患者腹水和囊液PTHrP浓度很高(> 500 pmol/L)。这些结果表明,PTHrP测定是有用的肿瘤标记物在某些情况下,卵巢肿瘤。

项目成果

期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
大西,神保ら: "周産期におけるPTH関連蛋白(PTHrP)の存在および分子動態" 日産婦誌. 47. S283 (1995)
Onishi, Jimbo 等人:“围产期 PTH 相关蛋白 (PTHrP) 的存在和分子动力学”Nissan Gyōshi 47. S283 (1995)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Onishi Y.et al: "Study on PTHrP in human milk, amniotic fluid and follicular fluid." Jpn J Obstet Gynecol. 47. S201 (1995)
Onishi Y.等人:“人乳、羊水和卵泡液中 PTHrP 的研究”。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kato, Y.et al: "PTHrP gene expression in ovarian carcinoma tissue and determination of immunoreactive PTHrP in sera and intratumor fluid obtained from patients with ovarian cancer." Jpn J Obstet Gynecol. 47. S132 (1995)
Kato, Y.等人:“卵巢癌组织中的 PTHrP 基因表达以及从卵巢癌患者获得的血清和肿瘤内液中免疫反应性 PTHrP 的测定。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Onishi Y.et al: "Detection of PTHrP in female reproductive organs and its molecular heterogeneity." Jpn J Obstet Gynecol. 45. S214 (1993)
Onishi Y.et al:“女性生殖器官中 PTHrP 的检测及其分子异质性。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hayashi K.et al: "Gene expression and localization of PTHrP in female reproductive organs and fetal tissues." Jpn J Obstet Gynecol. 47. S283 (1995)
Hayashi K.et al:“女性生殖器官和胎儿组织中 PTHrP 的基因表达和定位。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KATO Yoshio其他文献

KATO Yoshio的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KATO Yoshio', 18)}}的其他基金

Screening of fluorescently detectable RNA using evolutionary molecular engineering
利用进化分子工程筛选可荧光检测的RNA
  • 批准号:
    23655165
  • 财政年份:
    2011
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Functional system development towards screening of miRNA targets
筛选 miRNA 靶标的功能系统开发
  • 批准号:
    19710171
  • 财政年份:
    2007
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)

相似海外基金

Analysis of the biological roles of the vertebrate-specific, ovarian tumor (OTU) domain Fam105a protein
脊椎动物特异性卵巢肿瘤 (OTU) 结构域 Fam105a 蛋白的生物学作用分析
  • 批准号:
    RGPIN-2020-06225
  • 财政年份:
    2022
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Discovery Grants Program - Individual
Analysis of the biological roles of the vertebrate-specific, ovarian tumor (OTU) domain Fam105a protein
脊椎动物特异性卵巢肿瘤 (OTU) 结构域 Fam105a 蛋白的生物学作用分析
  • 批准号:
    RGPIN-2020-06225
  • 财政年份:
    2021
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Discovery Grants Program - Individual
Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy
在 PD-1 检查点治疗之前抑制肾上腺素信号传导以增强卵巢肿瘤微环境的免疫原性
  • 批准号:
    10355862
  • 财政年份:
    2021
  • 资助金额:
    $ 1.34万
  • 项目类别:
Development of ovarian tumor malignancy risk/histotype prediction system using multifaceted blood flow information with MRI
利用MRI多方面血流信息开发卵巢肿瘤恶性肿瘤风险/组织型预测系统
  • 批准号:
    20K16752
  • 财政年份:
    2020
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Analysis of the biological roles of the vertebrate-specific, ovarian tumor (OTU) domain Fam105a protein
脊椎动物特异性卵巢肿瘤 (OTU) 结构域 Fam105a 蛋白的生物学作用分析
  • 批准号:
    RGPIN-2020-06225
  • 财政年份:
    2020
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Discovery Grants Program - Individual
Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy
在 PD-1 检查点治疗之前抑制肾上腺素信号传导以增强卵巢肿瘤微环境的免疫原性
  • 批准号:
    10056699
  • 财政年份:
    2020
  • 资助金额:
    $ 1.34万
  • 项目类别:
Development of modified oncolytic virus targeting refractory relapsed ovarian tumor
针对难治性复发性卵巢肿瘤的改良溶瘤病毒的开发
  • 批准号:
    19K09751
  • 财政年份:
    2019
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
干扰素-γ在卵巢肿瘤微环境中选择性抑制 PARP 和 CTLA4 阻断的协同治疗机制
  • 批准号:
    10098009
  • 财政年份:
    2019
  • 资助金额:
    $ 1.34万
  • 项目类别:
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
干扰素-γ在卵巢肿瘤微环境中选择性抑制 PARP 和 CTLA4 阻断的协同治疗机制
  • 批准号:
    10334447
  • 财政年份:
    2019
  • 资助金额:
    $ 1.34万
  • 项目类别:
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
干扰素-γ在卵巢肿瘤微环境中选择性抑制 PARP 和 CTLA4 阻断的协同治疗机制
  • 批准号:
    10554264
  • 财政年份:
    2019
  • 资助金额:
    $ 1.34万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了